An expert review of novel hormone therapy in metastatic prostate cancer / 中华泌尿外科杂志

ABSTRACT

Prostate cancer is one of the most common male malignancies all over the world. Patients with metastatic prostate cancer (mPCa) have a poor prognosis compared to those with local disease. In China, most newly diagnosed patients are initially found with distant metastasis. Novel hormone therapies (NHT) develop rapidly in recent years. The randomized clinical trials have demonstrated significant benefits in prolonging overall survival and improving the quality of life. It is essential to choose and optimize regimens following the development of NHT. The article focuses on reviewing current and developing strategies, treatment selection, sequence, and combination in mPCa.